Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte (HUMA) announced positive Phase 3 trial results for its acellular tissue engineered vessel (ATEV) in high-risk end-stage renal disease patients needing arteriovenous access for hemodialysis. The trial demonstrated superior functional patency and usability compared to autologous arteriovenous fistulas (AVF) in a subgroup of patients at high risk of AVF maturation failure, specifically women, obese individuals, and those with diabetes; the ATEV also showed a comparable safety profile, suggesting a potential alternative where standard AVF procedures often fail. The company believes these results, presented at the Society for Vascular Surgery Vascular Annual Meeting, highlight a significant unmet need in a large segment of the dialysis access market.

Analysis

Humacyte, Inc. (HUMA) has presented positive and detailed results from its V007 Pivotal Phase 3 clinical trial for its acellular tissue engineered vessel (ATEV™) in high-risk end-stage renal disease (ESRD) patients requiring arteriovenous access for hemodialysis. The trial, involving 242 ESRD patients with 110 identified as high-risk for autologous arteriovenous fistula (AVF) maturation failure (defined as females, and males with BMI ≥30kg/m2 and diabetes), demonstrated that ATEV had superior functional patency and usability compared to traditional AVFs within this specific high-risk subgroup. Notably, the safety profile of ATEV was comparable to AVF, with similar low rates of infection, although the ATEV cohort experienced more thrombosis and stenosis events, the majority of which were successfully treated. A key advantage observed was that patients treated with ATEV required fewer maturation and surgical revision procedures. These findings, highlighted at the Society for Vascular Surgery Vascular Annual Meeting, are significant as the targeted high-risk patient population—comprising women and individuals with obesity and diabetes—constitutes over half of the dialysis access market and is currently underserved, with an approximate 50% failure rate for the standard AVF procedure. While Humacyte's ATEV received FDA approval in December 2024 for extremity vascular trauma, its application in AV access for hemodialysis remains investigational, with these strong Phase 3 results supporting its potential to address a clear unmet medical need. The company anticipates near-term publication of these V007 trial results in a major peer-reviewed medical journal.

Key Decisions for Investors

• The positive Phase 3 data for ATEV in high-risk hemodialysis patients significantly de-risks this specific indication and could substantially expand Humacyte's addressable market beyond its current vascular trauma approval, warranting a re-evaluation of the company's growth trajectory.
• Investors should closely monitor the upcoming publication of the full V007 trial data and subsequent regulatory interactions with the FDA for this AV access indication, as these will be key catalysts influencing the timeline to potential commercialization and market penetration.
• While the overall safety profile was comparable and benefits like reduced revisions are compelling, the higher incidence of thrombosis and stenosis with ATEV, even if manageable, should be considered as a potential factor in physician adoption and long-term performance compared to AVFs.
• Given that the targeted high-risk patient segment represents over 50% of the dialysis access market with high current treatment failure rates, successful development and approval of ATEV for this use could position Humacyte as a key solution provider for a significant unmet medical need.